$PFE

Breakthrough Properties said it bought Seagen’s 270,000 sq ft Everett, Wash. bio-manufacturing campus for $78 million and leased it for 21 years to an unnamed global biopharmaceutical company. Seagen spent about $350 million building it, but Pfizer, after acquiring Seagen for $43 billion in 2023, wound down construction. Breakthrough’s JV with Tishman Speyer and Bellco Capital declined tenant details.

The European Medicines Agency validated the application by Pfizer and Valneva for their Lyme disease vaccine candidate PF-07307405, and will begin assessing it. The Phase 3 VALOR trial in ages 5+ showed efficacy over 70% and no reported safety concerns. Valneva shares were up 24.96% to $7.06.

Pfizer and Valneva said the European Medicines Agency will review their experimental Lyme disease vaccine, PF-07307405. The companies reported trial results showing about 70% effectiveness in people aged 5 and older, with no approved vaccine currently. Valneva shares rose nearly 16% in Paris after the announcement.

EU officials agreed to study an experimental Lyme disease vaccine, according to Pfizer and Valneva. The firms said trials showed about 70% efficacy in ages 5+ and that the European Medicines Agency accepted an approval application for PF-07307405. Valneva shares rose about 16% in Paris trading.

The article says reported Lyme disease cases in Canada rose from 144 in 2009 to 5,809 in 2024, with 2025 preliminary cases at 7,105, citing PHAC data. It notes no human Lyme vaccine is currently approved. It describes Pfizer and Valneva’s co-developed vaccine PF-07307405 completing Phase 3 as of March 2026, and Moderna’s mRNA-1975 and mRNA-1982 in Phase 2.

Pfizer (PFE) and Valneva (VALN) said the European Medicines Agency validated their marketing authorization application for PF-07307405, a 6-valent OspA-based Lyme vaccine, moving it into formal review. The Phase 3 VALOR trial reported over 70% reduction in Lyme cases in ages 5+, with no safety concerns. Pfizer will manufacture and commercialize if approved.

Pfizer (PFE) and Valneva SE (VALN) said the European Medicines Agency (EMA) has validated their marketing authorization application for PF-07307405, their Lyme disease vaccine candidate. The validation starts the EMA review process, which could affect future regulatory timelines and commercialization prospects.

Pfizer (PFE) and Valneva (VALN/VLA) said the European Medicines Agency validated their marketing authorization application for PF-07307405, a 6-valent OspA-based Lyme disease vaccine candidate. The filing is based on Phase 3 VALOR results showing over 70% efficacy and no safety concerns. EMA will now assess the application.

Pfizer (NYSE: PFE) reported a net loss of $248 million in its quarter ended June 30, driven largely by $3.8 billion in impairment charges. Year to date, net income fell 58% to $2.4 billion. Over the past four quarters, free cash flow totaled $11 billion versus $9.8 billion in dividends, suggesting the payout may remain supported.

According to an analysis, Pfizer (PFE) returned about $49 billion to shareholders over five years, mostly dividends ($47 billion) versus $2.0 billion in buybacks. Despite the payouts, the stock’s total return over the period was -19.8% versus about +89% for the S&P 500. Pfizer cites 5% underlying revenue growth excluding declining COVID products, a $4.3 billion impairment, and guidance for high single-digit revenue CAGR and $9.7 billion net savings.